Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk

Paul K. Mills, Deborah G. Riordan, Rosemary D Cress, David F. Goldsmith

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Risk of epithelial ovarian cancer (EOC) attendant to use of hormone replacement therapy (HRT) was evaluated in a population-based case-control study of newly diagnosed EOC cases (n = 256) and randomly selected population controls (n = 1122). Telephone interviews were conducted to obtain information on history of HRT and several other covariates. Multivariate adjusted odds ratio (OR) and 95% confidence intervals (CI) were derived from unconditional logistic regression. The OR for ever use of HRT was 1.39 (95% CI: 1.01-1.93) compared to never use. Long-term use (>10 years) increased risk (OR: 1.62, CI: 1.05-2.50) although the trend p-value for duration of use was of only borderline significance (p = 0.08). The relationship was stronger in women without hysterectomy (OR: 1.66, 95% CI: 1.14-2.41) or tubal ligation (OR: 1.56, 95% CI: 1.08-2.26). In this study, use of HRT is associated with an increased risk of EOC.

Original languageEnglish (US)
Pages (from-to)124-132
Number of pages9
JournalCancer Detection and Prevention
Issue number2
StatePublished - 2005
Externally publishedYes


  • Epidemiology
  • Gynecologic cancer
  • Hormone replacement therapy
  • Risk factors

ASJC Scopus subject areas

  • Cancer Research
  • Oncology


Dive into the research topics of 'Hormone replacement therapy and invasive and borderline epithelial ovarian cancer risk'. Together they form a unique fingerprint.

Cite this